<DOC>
	<DOCNO>NCT02816645</DOCNO>
	<brief_summary>The study non-invasive reliable biomarkers track progression Parkinson 's disease ( PD ) essential disease-modifying treatment develop . Many clinical biological imaging biomarkers test `` gold standard '' find yet . Among , Magnetic Resonance Imaging ( MRI ) relaxometry use R2* measurement ( R2* = 1/T2* ) , validate marker estimate brain iron concentration , appear attractive technique safety , rapidly measure clinical condition ease ensure individual longitudinal follow-up . Current data cross sectional study R2* , show iron increase Substantia Nigra ( SN ) , lead suppose could biomarker disease vulnerability . Recently , investigator conduct first longitudinal follow-up R2* ( 1.5 T MRI ) , show rapid R2* increase part SN caudal putamen . We propose , , multicenter prospective study one-year cohort follow-up R2* variation ( ΔR2* ) three region interest ( ROIs ) ( SN , Ventral Tegmental Area ( VTA ) Putamen ) 160 patient PD , use 3 Tesla MRI , evaluate potential interest R2* biomarker disease progression . The variation R2* ( ΔR2* ) correlate clinical marker disease progress , non-motor symptom . 80 healthy control subject also include assess effect age cerebral physiological iron level .</brief_summary>
	<brief_title>One-year Follow-up Iron Basal Ganglia - R2* : Biomarker Parkinson 's Disease Progression ?</brief_title>
	<detailed_description>Use lay language . The study non-invasive reliable biomarkers track progression Parkinson 's disease essential disease-modifying treatment develop . Many clinical biological imaging biomarkers test `` gold standard '' find yet . Among , Magnetic Resonance Imaging ( MRI ) relaxometry use R2* measurement ( R2* = 1/T2* ) , validate marker estimate brain iron concentration , appear attractive technique safety , rapidly measure clinical condition ease ensure individual longitudinal follow-up . Current data cross sectional study R2* , show iron increase substantia nigra , lead suppose could biomarker disease vulnerability . Recently , conduct first longitudinal follow-up R2* ( 1.5 T MRI ) , show rapid R2* increase part SN caudal putamen . We propose , , multicenter prospective study one-year cohort follow-up R2* variation ( ΔR2* ) three region interest ( substantia nigra , ventral tegmental area putamen ) 160 patient Parkinson 's disease , use 3 Tesla MRI , evaluate potential interest R2* biomarker disease progression . The variation R2* ( ΔR2* ) correlate clinical marker disease progress , non-motor symptom . 80 healthy control subject also include assess effect age cerebral physiological iron level . Type study : Interventional multicenter prospective study cohort follow-up . Number center : 6 ( Clermont-Ferrand , Lyon , Grenoble , Paris , Limoges , Lille ) Study population : Recruitment 160 patient Parkinson 's disease divide four subgroup 40 patient accord disease duration : - &lt; 5 year - Between 5 10 year - Between 10 15 year - &gt; 15 year In parallel , 80 sex-age match healthy control subject match equally distribute 4 group ( n = 20/group ) base stratified plan gender age ( ratio 1:2 ) . Subjects assess twice , one year apart procedures detailed . The two neurological assessment make certified neurologist . Patients ' procedure : Visit 1 ( Day 0 ) ( duration : 1 day 2 half day ) - Signature informed consent form ( Day 0 ) . - Demographic clinical characteristic ( sex , age , disease duration , treatment ) . - Neurological evaluation . - Neuropsychological evaluation . - Self-administered questionnaire . - 1st MRI acquisition . Visit 2 ( Day 0 + 1 year ) ( duration : 1 day 2 half day ) - Current treatment ( ) , adverse event ( ) , serious adverse event ( ) . - Neurological evaluation . - Neuropsychological evaluation . - Self-administered questionnaire . - 2d MRI acquisition . Matched healthy control subject ' procedure : Visit 1 ( Day 0 ) ( duration : 1 half day ) - Signature informed consent form ( Day 0 ) . - Demographic clinical characteristic ( sex , age , disease duration , treatment ) . - Brief neuropsychological evaluation . - 1st MRI acquisition . Visit 2 ( Day 0 + 1 year ) ( duration : 1 half day ) - Current treatment ( ) , adverse event ( ) , serious adverse event ( ) . - Brief neuropsychological evaluation . - 2d MRI acquisition . MRI acquisition ( duration : 45 60 min ) The procedure perform 3 Tesla MRI , allow substantial gain signal-to-noise ratio compare one obtain 1.5 Tesla . Different sequence plan : - T2-weighted sequence * 3D GRE multi-echo . This sequence generate R2* map whole brain . - T1-weighted sequence high resolution 3D . This sequence allow anatomical characterization different brain structure help normalization T2* picture anatomical reference space . - T2* sequence 3D multiple gradient echo ( Spoiled Gradient Recalled echo sequence ) . This sequence measure decay rate NMR signal accord echo time . - 2D spin echo sequence T1-weighted neuromelanin . This sequence view substantia nigra locus coeruleus ( optional sequence ) . - Optional Diffusion-weighted sequence . This sequence determine movement water molecule brain infer main line connection neuron ( optional sequence ) . The R2* ( 1/T2* ) measure three different region interest ( substantia nigra , ventral tegmental area putamen ) 2 MRI 's order calculate ΔR2 .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Disease Progression</mesh_term>
	<criteria>Inclusion criterion PATIENTS : Parkinson 's Disease ( UK Parkinson 's Disease Society Brain Bank Criteria ) . No Deep Brain Stimulation ( DBS ) . From 40 80 year old . Inclusion criterion HEALTHY CONTROL SUBJECTS : From 40 80 year old . Exclusion criteria PATIENTS : Dementia ( MoCA &lt; 24 ) . Atypical parkinsonism ( MSA , PSP , … ) . Severe current psychiatric somatic disease . Iron treatment ( Desferal® ( deferoxamine ) , Ferriprox® ( deferiprone ) et Exjade® ( deferasirox ) , Fumafer® ( ferrous fumarate ) , Tardyferon® ( ferrous sulfate ( II ) ) , … ) , Ferinject® ( ferric carboxymaltose ) , Venofer® ( iron sucrose ) , … ) . Contraindication MRI ( claustrophobia , pace maker , … ) . Exclusion criterion HEALTHY CONTROL SUBJECTS : Neurological disease . Psychiatric somatic disease . Dementia ( MoCA &lt; 24 ) . Iron treatment ( Desferal® ( deferoxamine ) , Ferriprox® ( deferiprone ) et Exjade® ( deferasirox ) , Fumafer® ( ferrous fumarate ) , Tardyferon® ( ferrous sulfate ( II ) ) , … ) , Ferinject® ( ferric carboxymaltose ) , Venofer® ( iron sucrose ) , … ) . Contraindication MRI ( claustrophobia , pace maker , … ) .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Biomarker</keyword>
	<keyword>Iron</keyword>
	<keyword>R2*</keyword>
	<keyword>MRI</keyword>
	<keyword>Patients</keyword>
	<keyword>UK Parkinson 's Disease Society Brain Bank</keyword>
</DOC>